MedDataX Logo

Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

NCT ID: NCT00359801

Last Updated: 2010-02-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1976 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the long-term pulmonary and cardiovascular safety of Exubera in routine clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

NCT00136916

Diabetes Mellitus
TERMINATED PHASE3

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

NCT00139659

Asthma Diabetes Mellitus
COMPLETED PHASE3

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

NCT00138671

Diabetes Mellitus Chronic Obstructive Pulmonary Disease
TERMINATED PHASE3

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

NCT00391027

Diabetes Mellitus, Type 2
COMPLETED PHASE4

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes

NCT00424411

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pfizer announced in October 2007 that it would stop marketing Exubera. At that time, Pfizer committed to continued marketing until it returned the licensing rights for the technology to Nektar. Following the announcement, enrollment was halted. Subjects already enrolled and receiving treatment at the time of the halt in enrollment could continue in the study in accordance with the protocol. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, an amendment was filed on April 16, 2008 specifying that all subjects randomized to Exubera had to be transitioned to usual diabetes care, and all study subjects followed for serious adverse events for 6 months. In accordance with this amendment, study A2171069 was terminated on April 29, 2009. Neither safety nor efficacy reasons were the cause of the study termination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exubera

Group Type EXPERIMENTAL

Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care

Intervention Type DRUG

Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.

Usual Diabetes Care

Group Type ACTIVE_COMPARATOR

Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care

Intervention Type DRUG

Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care

Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.

Intervention Type DRUG

Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care

Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Non-Exubera

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eligible for receiving Exubera treatment based on the approved local label

Exclusion Criteria

* Pregnant or lactating
* Have a progressive fatal disease or a life expectancy that prohibits them from participating in a five-year research study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Bay Minette, Alabama, United States

Site Status

Pfizer Investigational Site

Fairhope, Alabama, United States

Site Status

Pfizer Investigational Site

Graysville, Alabama, United States

Site Status

Pfizer Investigational Site

Pell City, Alabama, United States

Site Status

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Forrest City, Arkansas, United States

Site Status

Pfizer Investigational Site

Searcy, Arkansas, United States

Site Status

Pfizer Investigational Site

Cudahy, California, United States

Site Status

Pfizer Investigational Site

El Cajon, California, United States

Site Status

Pfizer Investigational Site

Huntington Beach, California, United States

Site Status

Pfizer Investigational Site

Rolling Hills Estates, California, United States

Site Status

Pfizer Investigational Site

San Jose, California, United States

Site Status

Pfizer Investigational Site

Santa Ana, California, United States

Site Status

Pfizer Investigational Site

Westminster, California, United States

Site Status

Pfizer Investigational Site

Denver, Colorado, United States

Site Status

Pfizer Investigational Site

Milford, Connecticut, United States

Site Status

Pfizer Investigational Site

Wilmington, Delaware, United States

Site Status

Pfizer Investigational Site

Boca Raton, Florida, United States

Site Status

Pfizer Investigational Site

Clearwater, Florida, United States

Site Status

Pfizer Investigational Site

DeBary, Florida, United States

Site Status

Pfizer Investigational Site

Gainesville, Florida, United States

Site Status

Pfizer Investigational Site

Green Cove Springs, Florida, United States

Site Status

Pfizer Investigational Site

Hollywood, Florida, United States

Site Status

Pfizer Investigational Site

Kissimmee, Florida, United States

Site Status

Pfizer Investigational Site

Kissimmee, Florida, United States

Site Status

Pfizer Investigational Site

Marianna, Florida, United States

Site Status

Pfizer Investigational Site

Merritt Island, Florida, United States

Site Status

Pfizer Investigational Site

Miami, Florida, United States

Site Status

Pfizer Investigational Site

Niceville, Florida, United States

Site Status

Pfizer Investigational Site

Opa-locka, Florida, United States

Site Status

Pfizer Investigational Site

Orange City, Florida, United States

Site Status

Pfizer Investigational Site

Ormond Beach, Florida, United States

Site Status

Pfizer Investigational Site

Pembroke Pines, Florida, United States

Site Status

Pfizer Investigational Site

Plantation, Florida, United States

Site Status

Pfizer Investigational Site

Port Charlotte, Florida, United States

Site Status

Pfizer Investigational Site

Tampa, Florida, United States

Site Status

Pfizer Investigational Site

Tampa, Florida, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Conyers, Georgia, United States

Site Status

Pfizer Investigational Site

Decatur, Georgia, United States

Site Status

Pfizer Investigational Site

Warner Robins, Georgia, United States

Site Status

Pfizer Investigational Site

Boise, Idaho, United States

Site Status

Pfizer Investigational Site

Greenville, Illinois, United States

Site Status

Pfizer Investigational Site

Libertyville, Illinois, United States

Site Status

Pfizer Investigational Site

Fishers, Indiana, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Des Moines, Iowa, United States

Site Status

Pfizer Investigational Site

Louisville, Kentucky, United States

Site Status

Pfizer Investigational Site

Mount Sterling, Kentucky, United States

Site Status

Pfizer Investigational Site

Bossier City, Louisiana, United States

Site Status

Pfizer Investigational Site

Auburn, Maine, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Elkton, Maryland, United States

Site Status

Pfizer Investigational Site

Glen Burnie, Maryland, United States

Site Status

Pfizer Investigational Site

Wheaton, Maryland, United States

Site Status

Pfizer Investigational Site

Boston, Massachusetts, United States

Site Status

Pfizer Investigational Site

Plymouth, Massachusetts, United States

Site Status

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Site Status

Pfizer Investigational Site

Battle Creek, Michigan, United States

Site Status

Pfizer Investigational Site

Battle Creek, Michigan, United States

Site Status

Pfizer Investigational Site

Clinton, Michigan, United States

Site Status

Pfizer Investigational Site

Flint, Michigan, United States

Site Status

Pfizer Investigational Site

Muskegon, Michigan, United States

Site Status

Pfizer Investigational Site

Sterling Heights, Michigan, United States

Site Status

Pfizer Investigational Site

Troy, Michigan, United States

Site Status

Pfizer Investigational Site

Warren, Michigan, United States

Site Status

Pfizer Investigational Site

Saint Cloud, Minnesota, United States

Site Status

Pfizer Investigational Site

Grand Island, Nebraska, United States

Site Status

Pfizer Investigational Site

Incline Village, Nevada, United States

Site Status

Pfizer Investigational Site

Belleville, New Jersey, United States

Site Status

Pfizer Investigational Site

Belvidere, New Jersey, United States

Site Status

Pfizer Investigational Site

Glendora, New Jersey, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Babylon, New York, United States

Site Status

Pfizer Investigational Site

Brooklyn, New York, United States

Site Status

Pfizer Investigational Site

New Hartford, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Williamsville, New York, United States

Site Status

Pfizer Investigational Site

Asheboro, North Carolina, United States

Site Status

Pfizer Investigational Site

Charlotte, North Carolina, United States

Site Status

Pfizer Investigational Site

Morehead City, North Carolina, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Shelby, North Carolina, United States

Site Status

Pfizer Investigational Site

Tabor City, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Bismarck, North Dakota, United States

Site Status

Pfizer Investigational Site

Ashtabula, Ohio, United States

Site Status

Pfizer Investigational Site

Canton, Ohio, United States

Site Status

Pfizer Investigational Site

Cleveland, Ohio, United States

Site Status

Pfizer Investigational Site

Columbus, Ohio, United States

Site Status

Pfizer Investigational Site

Dayton, Ohio, United States

Site Status

Pfizer Investigational Site

McConnelsville, Ohio, United States

Site Status

Pfizer Investigational Site

Zanesville, Ohio, United States

Site Status

Pfizer Investigational Site

Clinton, Oklahoma, United States

Site Status

Pfizer Investigational Site

Bend, Oregon, United States

Site Status

Pfizer Investigational Site

Broomall, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Dauphin, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Fogelsville, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Hanover, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Harrisburg, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Jeannette, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Jenkintown, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Jersey Shore, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Norristown, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Plymouth Meeting, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Tipton, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Charleston, South Carolina, United States

Site Status

Pfizer Investigational Site

Florence, South Carolina, United States

Site Status

Pfizer Investigational Site

Greer, South Carolina, United States

Site Status

Pfizer Investigational Site

North Myrtle Beach, South Carolina, United States

Site Status

Pfizer Investigational Site

Germantown, Tennessee, United States

Site Status

Pfizer Investigational Site

Corpus Christi, Texas, United States

Site Status

Pfizer Investigational Site

Garland, Texas, United States

Site Status

Pfizer Investigational Site

Hurst, Texas, United States

Site Status

Pfizer Investigational Site

Kaufman, Texas, United States

Site Status

Pfizer Investigational Site

Lubbock, Texas, United States

Site Status

Pfizer Investigational Site

Midland, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

San Marcos, Texas, United States

Site Status

Pfizer Investigational Site

Stephenville, Texas, United States

Site Status

Pfizer Investigational Site

Webster, Texas, United States

Site Status

Pfizer Investigational Site

Layton, Utah, United States

Site Status

Pfizer Investigational Site

Chesapeake, Virginia, United States

Site Status

Pfizer Investigational Site

Ettrick, Virginia, United States

Site Status

Pfizer Investigational Site

Burnsville, West Virginia, United States

Site Status

Pfizer Investigational Site

Charleston, West Virginia, United States

Site Status

Pfizer Investigational Site

Aschaffenburg, , Germany

Site Status

Pfizer Investigational Site

Bad Doberan, , Germany

Site Status

Pfizer Investigational Site

Bad Grönenbach, , Germany

Site Status

Pfizer Investigational Site

Bad Oeynhausen, , Germany

Site Status

Pfizer Investigational Site

Bad Staffelstein, , Germany

Site Status

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Bonn, , Germany

Site Status

Pfizer Investigational Site

Chemnitz, , Germany

Site Status

Pfizer Investigational Site

Cologne, , Germany

Site Status

Pfizer Investigational Site

Datteln, , Germany

Site Status

Pfizer Investigational Site

Dortmund, , Germany

Site Status

Pfizer Investigational Site

Dortmund, , Germany

Site Status

Pfizer Investigational Site

Eisenach, , Germany

Site Status

Pfizer Investigational Site

Emden, , Germany

Site Status

Pfizer Investigational Site

Essen, , Germany

Site Status

Pfizer Investigational Site

Esslingen am Neckar, , Germany

Site Status

Pfizer Investigational Site

Falkensee, , Germany

Site Status

Pfizer Investigational Site

Friedberg, , Germany

Site Status

Pfizer Investigational Site

Fulda, , Germany

Site Status

Pfizer Investigational Site

Hagen, , Germany

Site Status

Pfizer Investigational Site

Hamburg, , Germany

Site Status

Pfizer Investigational Site

Hamburg, , Germany

Site Status

Pfizer Investigational Site

Hohenmölsen, , Germany

Site Status

Pfizer Investigational Site

Jena, , Germany

Site Status

Pfizer Investigational Site

Leverkusen, , Germany

Site Status

Pfizer Investigational Site

Mahlberg, , Germany

Site Status

Pfizer Investigational Site

Mannheim, , Germany

Site Status

Pfizer Investigational Site

Markdorf, , Germany

Site Status

Pfizer Investigational Site

Marl, , Germany

Site Status

Pfizer Investigational Site

Meissen, , Germany

Site Status

Pfizer Investigational Site

Münster, , Germany

Site Status

Pfizer Investigational Site

Münster, , Germany

Site Status

Pfizer Investigational Site

Neuwied, , Germany

Site Status

Pfizer Investigational Site

Nuremberg, , Germany

Site Status

Pfizer Investigational Site

Reinfeld, , Germany

Site Status

Pfizer Investigational Site

Riesa, , Germany

Site Status

Pfizer Investigational Site

Schlüchtern, , Germany

Site Status

Pfizer Investigational Site

Siegen, , Germany

Site Status

Pfizer Investigational Site

Suhl, , Germany

Site Status

Pfizer Investigational Site

Villingen-Schwenningen, , Germany

Site Status

Pfizer Investigational Site

Wangen, , Germany

Site Status

Pfizer Investigational Site

Wangen I. Allgaeu, , Germany

Site Status

Pfizer Investigational Site

Warburg, , Germany

Site Status

Pfizer Investigational Site

Manatí, , Puerto Rico

Site Status

Pfizer Investigational Site

Borås, , Sweden

Site Status

Pfizer Investigational Site

Forshaga, , Sweden

Site Status

Pfizer Investigational Site

Gothenburg, , Sweden

Site Status

Pfizer Investigational Site

Lilla Edet, , Sweden

Site Status

Pfizer Investigational Site

Chesterfield, Derbyshire, United Kingdom

Site Status

Pfizer Investigational Site

Ashford, Middlesex, United Kingdom

Site Status

Pfizer Investigational Site

Dronfield, Sheffield, United Kingdom

Site Status

Pfizer Investigational Site

Weybridge, SURREY, United Kingdom

Site Status

Pfizer Investigational Site

Woking, Surrey, United Kingdom

Site Status

Pfizer Investigational Site

Rugby, Warwickshire, United Kingdom

Site Status

Pfizer Investigational Site

Warminster, WILTSHIRE, United Kingdom

Site Status

Pfizer Investigational Site

Sheffield, Yorkshire, United Kingdom

Site Status

Pfizer Investigational Site

Airdrie, , United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Birmingham, , United Kingdom

Site Status

Pfizer Investigational Site

Leicester, , United Kingdom

Site Status

Pfizer Investigational Site

Newcastle upon Tyne, , United Kingdom

Site Status

Pfizer Investigational Site

Newcastle upon Tyne, , United Kingdom

Site Status

Pfizer Investigational Site

Westbury, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany Puerto Rico Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Gatto NM, Bracken MB, Kolitsopoulos F, Duggan WT, Koch GG, Wise RA, Jackson NC. Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME). Contemp Clin Trials Commun. 2019 Aug 13;18:100427. doi: 10.1016/j.conctc.2019.100427. eCollection 2020 Jun.

Reference Type DERIVED
PMID: 32478195 (View on PubMed)

Kolitsopoulos FM, Gatto NM, Sweetland K, Bracken MB, Jackson N. Implications of product withdrawal on a post-approval pragmatic trial: The VOLUME study experience. Contemp Clin Trials Commun. 2019 Oct 28;16:100477. doi: 10.1016/j.conctc.2019.100477. eCollection 2019 Dec.

Reference Type DERIVED
PMID: 31799472 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2171069&StudyName=Exubera%20Large%20Simple%20Trial%20To%20Evaluate%20Long-Term%20Pulmonary%20And%20Cardiovascular%20Safety

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A2171069

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus
NCT00282971 TERMINATED PHASE3
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
NCT00143247 TERMINATED PHASE2
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
NCT00437489 TERMINATED PHASE4
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
NCT00356421 TERMINATED PHASE4
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
NCT00137046 TERMINATED PHASE3
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
NCT00418522 COMPLETED PHASE4
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
NCT00479258 TERMINATED PHASE3
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
NCT00370565 COMPLETED PHASE3
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
NCT00367445 COMPLETED PHASE4
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
NCT00134147 COMPLETED PHASE3
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
NCT00348374 COMPLETED PHASE3
US Inhaled Insulin Dose Titration Study
NCT00246623 COMPLETED PHASE3
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
NCT01060059 COMPLETED
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
NCT01144338 COMPLETED PHASE3
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
NCT00523042 TERMINATED PHASE3
Follow-Up Study for Exubera
NCT00734591 COMPLETED
Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes
NCT00315952 COMPLETED PHASE4
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
NCT01798914 NO_LONGER_AVAILABLE
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
NCT00150410 COMPLETED PHASE3
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
NCT00103935 COMPLETED PHASE2
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
NCT00472953 TERMINATED PHASE3
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
NCT00516048 COMPLETED PHASE3
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
NCT00308139 COMPLETED PHASE3
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382
NCT03341013 COMPLETED PHASE1
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
NCT00331604 TERMINATED PHASE3